NRx Pharmaceuticals has announced the completion of its registered direct offering for 9,670,002 shares of common stock at $0.65 per share, resulting in gross proceeds of approximately $6.28 million before deducting placement agent fees and other expenses. The company intends to use net proceeds from the offering for working capital and general corporate purposes, as well as potentially using it to initiate research into the use of NRX-101 for treating PTSD and chronic pain. H.C. Wainwright & Co acted as an exclusive placement agent for this offering. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, particularly bipolar depression with suicidality and post-traumatic stress disorder (PTSD).
Keywords: NRx Pharmaceuticals, registered direct offering, common stock, H.C. Wainwright & Co., PTSD
The funds raised from the registered direct offering will help NRx Pharmaceuticals further develop their therapeutic treatments for mental health disorders such as bipolar depression with suicidality and PTSD. The company may also use some of the funds to conduct research on new treatment options for these conditions. This funding will enable NRx Pharmaceuticals to continue working towards improving patient outcomes and quality of life through innovative medical solutions.